This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
acute respiratory | 361 |
respiratory syndrome | 338 |
novel coronavirus | 329 |
coronavirus disease | 238 |
public health | 236 |
severe acute | 210 |
infectious diseases | 190 |
syndrome coronavirus | 190 |
middle east | 183 |
east respiratory | 154 |
respiratory tract | 154 |
infect dis | 154 |
doc id | 151 |
dis doi | 151 |
cord uid | 151 |
world health | 127 |
health organization | 119 |
confirmed cases | 116 |
south korea | 114 |
saudi arabia | 114 |
respiratory infections | 114 |
kawasaki disease | 111 |
clinical characteristics | 103 |
risk factors | 103 |
severe covid | 98 |
mass gatherings | 98 |
human metapneumovirus | 96 |
viral load | 96 |
health care | 93 |
respiratory viruses | 91 |
systematic review | 91 |
hong kong | 88 |
ebola virus | 83 |
infectious disease | 83 |
cytokine storm | 82 |
reproduction number | 81 |
hajj pilgrims | 79 |
influenza virus | 77 |
standard precautions | 76 |
critically ill | 74 |
mass gathering | 73 |
viral shedding | 69 |
authors declare | 69 |
social distancing | 69 |
cohort study | 68 |
respiratory syncytial | 68 |
hospitalized patients | 67 |
syncytial virus | 66 |
lopinavir ritonavir | 65 |
intensive care | 65 |
global health | 64 |
respiratory distress | 63 |
clinical features | 62 |
disease control | 62 |
cov infection | 61 |
tract infections | 61 |
avian influenza | 60 |
african countries | 60 |
hubei province | 58 |
control measures | 57 |
ill patients | 57 |
control group | 57 |
virus disease | 56 |
virus infection | 55 |
mechanical ventilation | 55 |
distress syndrome | 54 |
primary care | 54 |
personal protective | 53 |
reactive protein | 53 |
symptom onset | 52 |
disease severity | 52 |
mainland china | 52 |
incubation period | 51 |
antigen test | 51 |
united states | 51 |
chronic typhoid | 51 |
pandemic influenza | 50 |
healthcare workers | 50 |
imported cases | 50 |
infected patients | 50 |
statistically significant | 49 |
viral infections | 48 |
fatality rate | 47 |
health systems | 47 |
infection control | 47 |
study period | 47 |
coronavirus pneumonia | 47 |
physical distancing | 46 |
upper respiratory | 46 |
significantly higher | 46 |
respiratory symptoms | 46 |
previous studies | 45 |
patients infected | 45 |
staphylococcus aureus | 45 |
isolation wards | 44 |
acquired pneumonia | 44 |
present study | 44 |
typhoid carriers | 44 |
least one | 44 |
years old | 43 |
time series | 43 |
immune response | 43 |
respiratory infection | 42 |
polymerase chain | 42 |
chain reaction | 42 |
nasopharyngeal swabs | 41 |
cp therapy | 41 |
neurosensory dysfunction | 40 |
respiratory failure | 40 |
confirmed covid | 40 |
nucleic acid | 40 |
first case | 40 |
travel restrictions | 39 |
care unit | 39 |
coronavirus infection | 39 |
increased risk | 39 |
mortality rate | 39 |
severe disease | 39 |
reported cases | 39 |
distancing measures | 39 |
care workers | 39 |
viral loads | 39 |
severe pneumonia | 38 |
high risk | 38 |
personal relationships | 36 |
human transmission | 35 |
convalescent plasma | 35 |
transmission dynamics | 35 |
general population | 35 |
age groups | 35 |
logistic regression | 34 |
chest ct | 34 |
plasma exchange | 33 |
nasopharyngeal swab | 33 |
significant difference | 33 |
among patients | 33 |
financial interests | 33 |
clinical course | 33 |
lower respiratory | 32 |
hand hygiene | 32 |
competing financial | 32 |
west africa | 32 |
contact tracing | 32 |
human coronavirus | 32 |
clinical outcomes | 32 |
emerging infectious | 31 |
work reported | 31 |
hmpv infection | 31 |
tested positive | 31 |
health security | 31 |
serial interval | 31 |
sierra leone | 31 |
epidemiological characteristics | 31 |
two groups | 31 |
performed using | 30 |
respiratory virus | 30 |
influenza viruses | 30 |
google trends | 30 |
oropharyngeal swabs | 30 |
protective measures | 30 |
marburg virus | 30 |
new cases | 30 |
two weeks | 30 |
known competing | 30 |
total number | 30 |
pharmaceutical interventions | 30 |
respiratory pathogens | 29 |
typhoid cases | 29 |
modelling study | 29 |
hand washing | 29 |
clinical trials | 29 |
influenza pandemic | 29 |
asymptomatic cases | 29 |
viral rna | 29 |
saharan africa | 29 |
tract infection | 29 |
national health | 29 |
resistant staphylococcus | 29 |
case series | 29 |
young children | 28 |
hospital admission | 28 |
severe cases | 28 |
infected pneumonia | 28 |
early phase | 28 |
local cases | 28 |
acute typhoid | 28 |
sample size | 28 |
disaster risk | 28 |
early stage | 28 |
study design | 28 |
shedding duration | 28 |
sendai framework | 28 |
data collection | 28 |
retrospective cohort | 28 |
respiratory viral | 27 |
reverse transcription | 27 |
cytokine release | 27 |
informed consent | 27 |
university hospital | 27 |
retrospective study | 27 |
supplementary table | 27 |
preventive measures | 27 |
new york | 27 |
case fatality | 26 |
protective equipment | 26 |
day mortality | 26 |
recent study | 26 |
one health | 26 |
second wave | 26 |
asymptomatic patients | 26 |
factors associated | 26 |
income countries | 25 |
organ failure | 25 |
clinical trial | 25 |
release syndrome | 25 |
community transmission | 25 |
family members | 25 |
cardiac injury | 25 |
south africa | 25 |
among children | 25 |
prediction model | 25 |
like illness | 25 |
ethics committee | 25 |
patients received | 25 |
severe patients | 25 |
mean age | 25 |
mast cell | 25 |
health literacy | 25 |
detection rate | 24 |
viral infection | 24 |
adverse events | 24 |
severe illness | 24 |
high viral | 24 |
infected individuals | 24 |
median age | 24 |
dew point | 24 |
within days | 24 |
another study | 24 |
streptococcus pneumoniae | 24 |
test results | 24 |
close contact | 24 |
ethical approval | 24 |
ncov infection | 24 |
laboratory tests | 23 |
suspected cases | 23 |
controlled trial | 23 |
developing countries | 23 |
standard deviation | 23 |
million people | 23 |
respiratory specimens | 23 |
cardiovascular disease | 23 |
blood culture | 23 |
new coronavirus | 22 |
descriptive study | 22 |
hospital stay | 22 |
ritonavir group | 22 |
respiratory illness | 22 |
clinical presentation | 22 |
age group | 22 |
immune responses | 22 |
asymptomatic infections | 22 |
international health | 22 |
risk prediction | 22 |
oxygen saturation | 22 |
contact history | 22 |
asymptomatic individuals | 22 |
effective reproduction | 22 |
vital signs | 22 |
among pilgrims | 22 |
medical records | 22 |
prospective study | 22 |
generation spread | 22 |
infections among | 21 |
patients treated | 21 |
two categories | 21 |
observational study | 21 |
oropharyngeal swab | 21 |
oxygen therapy | 21 |
viral transmission | 21 |
southeast asia | 21 |
demographic characteristics | 21 |
viral respiratory | 21 |
truck drivers | 21 |
influenza vaccine | 21 |
cell activation | 21 |
infection prevention | 21 |
categorical variables | 21 |
included studies | 21 |
population density | 21 |
outside hubei | 21 |
antiviral treatment | 21 |
confidence interval | 21 |
health regulations | 21 |
cases reported | 21 |
parainfluenza virus | 21 |
among hajj | 21 |
first week | 21 |
basic reproduction | 21 |
health authorities | 21 |
immunocompromised patients | 21 |
seasonal influenza | 20 |
coronavirus infections | 20 |
generation spreads | 20 |
hajj pilgrimage | 20 |
lymphocyte count | 20 |
genomic mrna | 20 |
several studies | 20 |
transmission potential | 20 |
one study | 20 |
lung disease | 20 |
metapneumovirus infection | 20 |
epidemic spread | 20 |
diagnostic tests | 20 |
health measures | 20 |
infection among | 20 |
time reverse | 20 |
disease surveillance | 20 |
significant differences | 20 |
primary endpoint | 20 |
health emergency | 20 |
severe group | 20 |
clinical practice | 20 |
effective treatment | 20 |
risk reduction | 20 |
pdf file | 20 |
neutralizing antibodies | 20 |
pcr test | 20 |
coronary artery | 20 |
epidemic potential | 20 |
travel history | 20 |
urine antigen | 19 |
cell count | 19 |
elderly patients | 19 |
viral pathogens | 19 |
significantly lower | 19 |
tocilizumab therapy | 19 |
control study | 19 |
symptoms onset | 19 |
growth rate | 19 |
global pandemic | 19 |
higher risk | 19 |
viral clearance | 19 |
continuous variables | 19 |
laboratory data | 19 |
case report | 19 |
case definition | 19 |
treated patients | 18 |
health commission | 18 |
diamond princess | 18 |
predictive value | 18 |
evaluation version | 18 |
cap cases | 18 |
corona virus | 18 |
health workers | 18 |
baseline characteristics | 18 |
secondary cases | 18 |
th case | 18 |
healthcare system | 18 |
children aged | 18 |
ct scan | 18 |
tcz group | 18 |
lung injury | 18 |
gyeonggi province | 18 |
tcz administration | 18 |
severe sars | 18 |
large number | 18 |
statistical significance | 18 |
two cases | 18 |
different types | 18 |
air pollution | 18 |
laboratory findings | 18 |
health services | 17 |
seven days | 17 |
peripheral blood | 17 |
files without | 17 |
many countries | 17 |
median time | 17 |
white blood | 17 |
generate pdf | 17 |
septic shock | 17 |
early stages | 17 |
close contacts | 17 |
epidemic sources | 17 |
novaferon plus | 17 |
mortality rates | 17 |
nervous system | 17 |
plus lopinavir | 17 |
influenza vaccination | 17 |
sputum samples | 17 |
pdf files | 17 |
international travel | 17 |
healthcare settings | 17 |
positive rate | 17 |
based studies | 17 |
important role | 17 |
data analysis | 17 |
proprotein convertase | 16 |
australian hajj | 16 |
randomized clinical | 16 |
may also | 16 |
hospital setting | 16 |
genomic rna | 16 |
optimum pool | 16 |
disease outbreaks | 16 |
per day | 16 |
universal precautions | 16 |
coronavirus outbreak | 16 |
family cluster | 16 |
less likely | 16 |
ill covid | 16 |
sore throat | 16 |
saudi moh | 16 |
meningococcal disease | 16 |
current study | 16 |
yellow fever | 16 |
statistical analysis | 16 |
igg antibodies | 16 |
funding agencies | 16 |
central nervous | 16 |
observational cohort | 16 |
face masks | 16 |
significantly associated | 16 |
doubling time | 16 |
drug administration | 16 |
patients died | 16 |
competing interests | 16 |
critical illness | 16 |
virus infections | 16 |
patients hospitalized | 16 |
requiring hospitalization | 16 |
much higher | 16 |
heart rate | 16 |
asymptomatic covid | 16 |
cell culture | 16 |
epithelial cells | 16 |
pool size | 16 |
local transmission | 16 |
hospitalized children | 16 |
respiratory parameters | 15 |
multivariate analysis | 15 |
sars coronavirus | 15 |
multiple organ | 15 |
clinical manifestations | 15 |
influenza infection | 15 |
convertase subtilisin | 15 |
hiv infection | 15 |
touch surfaces | 15 |
ambient air | 15 |
immune system | 15 |
epidemic process | 15 |
laboratory diagnosis | 15 |
first two | 15 |
saudi ministry | 15 |
diabetes mellitus | 15 |
control strategies | 15 |
prospective cohort | 15 |
positive cases | 15 |
high mortality | 15 |
sectional study | 15 |
nasal swabs | 15 |
inflammatory response | 15 |
mobile devices | 15 |
clinical specimens | 15 |
human respiratory | 15 |
severe respiratory | 15 |
inclusion criteria | 15 |
mesenchymal stem | 15 |
stem cells | 15 |
igm antibodies | 15 |
ct values | 15 |
february th | 15 |
one case | 15 |
pandemic potential | 15 |
febrile illness | 15 |
aged years | 15 |
varying reproduction | 15 |
haemorrhagic fever | 15 |
nonhuman primates | 15 |
publicly available | 15 |
inflammatory cytokines | 15 |
computed tomography | 15 |
oxygen support | 15 |
people aged | 15 |
surveillance systems | 14 |
converting enzyme | 14 |
risk factor | 14 |
novel human | 14 |
emerging diseases | 14 |
total score | 14 |
community cases | 14 |
amino acid | 14 |
study population | 14 |
gathering events | 14 |
viral detection | 14 |
disseminated intravascular | 14 |
positive patients | 14 |
amino acids | 14 |
infected cases | 14 |
study conducted | 14 |
mg iv | 14 |
climate change | 14 |
bacterial infections | 14 |
human immunodeficiency | 14 |
pcr assay | 14 |
body temperature | 14 |
lymphocyte counts | 14 |
southern china | 14 |
inflammatory markers | 14 |
patients receiving | 14 |
case data | 14 |
intravascular coagulation | 14 |
among australian | 14 |
alveolar damage | 14 |
clinical data | 14 |
zika virus | 14 |
childhood pneumonia | 14 |
viral pneumonia | 14 |
mesenchymal stromal | 14 |
immunodeficiency virus | 14 |
fruit bats | 14 |
newly confirmed | 14 |
spread rapidly | 14 |
stem cell | 14 |
international concern | 14 |
emergency response | 14 |
elderly people | 14 |
critical patients | 14 |
hajj season | 14 |
clinical symptoms | 14 |
exponential growth | 14 |
taste disorders | 14 |
endemic countries | 14 |
ng ml | 14 |
icu admission | 14 |
treatment initiation | 14 |
spatial association | 14 |
healthcare facilities | 13 |
oral mucosa | 13 |
several limitations | 13 |
case reports | 13 |
hiv cases | 13 |
mathematical model | 13 |
sporting events | 13 |
cruise ship | 13 |
poor outcome | 13 |
study showed | 13 |
venous thromboembolism | 13 |
may lead | 13 |
blood samples | 13 |
mild symptoms | 13 |
testing capacity | 13 |
cycle threshold | 13 |
control subjects | 13 |
chest radiography | 13 |
tract specimens | 13 |
spanish influenza | 13 |
significantly different | 13 |
rapid spread | 13 |
time rt | 13 |
respiratory rate | 13 |
leading cause | 13 |
crp levels | 13 |
statistical difference | 13 |
poor prognosis | 13 |
interquartile range | 13 |
diagnostic test | 13 |
nha trang | 13 |
real time | 13 |
exact test | 13 |
pregnant women | 13 |
specific grant | 13 |
incidence rate | 13 |
first wave | 13 |
sexual transmission | 13 |
confirmed case | 13 |
surveillance system | 13 |
africa cdc | 13 |
situation report | 13 |
crf bc | 13 |
national institute | 13 |
cases among | 13 |
blood cell | 13 |
communicable diseases | 13 |
care units | 13 |
reverse transcriptase | 13 |
fungal infections | 13 |
general self | 13 |
time pcr | 13 |
reproduction numbers | 13 |
time interval | 13 |
common respiratory | 13 |
wbc count | 13 |
travel advice | 13 |
york city | 13 |
wuhan city | 13 |
reproductive number | 13 |
transcription polymerase | 13 |
different countries | 13 |
preliminary report | 13 |
march th | 13 |
mild patients | 13 |
recovery time | 13 |
activation syndrome | 13 |
pneumonia patients | 13 |
respiratory disease | 13 |
monoclonal antibody | 13 |
iv group | 12 |
mg dl | 12 |
statistical analyses | 12 |
total cases | 12 |
infected patient | 12 |
laboratory results | 12 |
laboratory test | 12 |
pcr assays | 12 |
first reported | 12 |
also found | 12 |
lung lesions | 12 |
detection rates | 12 |
wavelet transform | 12 |
confirmed sars | 12 |
patients showed | 12 |
vp protein | 12 |
second week | 12 |
human influenza | 12 |
princess cruise | 12 |
recent studies | 12 |
high levels | 12 |
results showed | 12 |
molecular methods | 12 |
rna extraction | 12 |
healthy control | 12 |
viral replication | 12 |
case study | 12 |
outbreak investigation | 12 |
older age | 12 |
etiological agent | 12 |
pleural effusion | 12 |
general hospital | 12 |
french pilgrims | 12 |
supplementary material | 12 |
patients without | 12 |
pneumonia requiring | 12 |
typical symptoms | 12 |
viral culture | 12 |
mers coronavirus | 12 |
pulmonary embolism | 12 |
antibiotic prescription | 12 |
conducted using | 12 |
surgical residents | 12 |
positive results | 12 |
global spread | 12 |
randomized controlled | 12 |
old man | 12 |
au ml | 12 |
united kingdom | 12 |
risk assessment | 12 |
agents detected | 12 |
blood donors | 12 |
viruses detected | 12 |
enteric fever | 12 |
diagnostic criteria | 12 |
patients admitted | 12 |
negative results | 12 |
person transmission | 12 |
baseline survey | 12 |
applied biosystems | 12 |
asymptomatic carriers | 12 |
heart disease | 12 |
antiviral drugs | 12 |
mast cells | 12 |
profit sectors | 12 |
mers cases | 12 |
clinical management | 12 |
mild group | 12 |
epidemiological data | 12 |
mortality risk | 12 |
annual hajj | 12 |
young adults | 12 |
meteorological parameters | 12 |
clearance rates | 12 |
pneumococcal disease | 12 |
asymptomatic sars | 12 |
international society | 12 |
one week | 12 |
target prevalence | 12 |
high level | 11 |
kawasaki syndrome | 11 |
respiration rate | 11 |
environmental contamination | 11 |
studies showed | 11 |
propensity score | 11 |
sars patients | 11 |
facial skin | 11 |
hiv aids | 11 |
two patients | 11 |
health system | 11 |
treatment groups | 11 |
medical staff | 11 |
small number | 11 |
international spread | 11 |
pg ml | 11 |
early transmission | 11 |
human coronaviruses | 11 |
ebola epidemic | 11 |
considered statistically | 11 |
randomised controlled | 11 |
institutional review | 11 |
pneumococcal pneumonia | 11 |
seasonal patterns | 11 |
trends tm | 11 |
renal failure | 11 |
severe critical | 11 |
gastrointestinal symptoms | 11 |
antibody responses | 11 |
adult patients | 11 |
medical practitioners | 11 |
influenza prevention | 11 |
member states | 11 |
acute febrile | 11 |
disease outbreak | 11 |
early diagnosis | 11 |
correlation coefficient | 11 |
antigen detection | 11 |
infection may | 11 |
severe cap | 11 |
epidemiological studies | 11 |
public interest | 11 |
health approach | 11 |
chest radiographs | 11 |
ct value | 11 |
laboratory confirmed | 11 |
three days | 11 |
organ dysfunction | 11 |
also reported | 11 |
icu patients | 11 |
contaminated area | 11 |
lymphocyte subsets | 11 |
spike protein | 11 |
case counts | 11 |
blood pressure | 11 |
ground glass | 11 |
human bocavirus | 11 |
glass opacities | 11 |
false negative | 11 |
serological tests | 11 |
major public | 11 |
attack rate | 11 |
antiviral therapy | 11 |
ebola outbreak | 11 |
united nations | 11 |
standard treatment | 11 |
study reported | 11 |
based study | 11 |
antimicrobial resistance | 11 |
middle income | 11 |
odds ratio | 11 |
irt system | 11 |
symptomatic surveillance | 11 |
epidemic curve | 11 |
influenza transmission | 11 |
transplant recipients | 11 |
face mask | 11 |
among health | 11 |
even though | 11 |
long term | 10 |
vaccine development | 10 |
may th | 10 |
mouth disease | 10 |
patients presenting | 10 |
nosocomial transmission | 10 |
among idus | 10 |
cov outbreak | 10 |
single center | 10 |
virus outbreak | 10 |
olfactory dysfunction | 10 |
influenza patients | 10 |
old woman | 10 |
excluding wuhan | 10 |
mg daily | 10 |
underlying diseases | 10 |
younger people | 10 |
health education | 10 |
emerging respiratory | 10 |
st group | 10 |
review board | 10 |
skin temperature | 10 |
early outbreak | 10 |
european countries | 10 |
chinese center | 10 |
disease burden | 10 |
asymptomatic carrier | 10 |
positive predictive | 10 |
uptake among | 10 |
hospital infections | 10 |
among people | 10 |
disease spread | 10 |
tpe group | 10 |
thermal images | 10 |
infection rate | 10 |
twice daily | 10 |
rheumatoid arthritis | 10 |
tertiary care | 10 |
dromedary camels | 10 |
sustained transmission | 10 |
readily available | 10 |
lockdown measures | 10 |
severe forms | 10 |
stromal cells | 10 |
normal range | 10 |
mg twice | 10 |
negative predictive | 10 |
qualified proportion | 10 |
adult inpatients | 10 |
diagnostic testing | 10 |
diffuse alveolar | 10 |
early detection | 10 |
general hospitals | 10 |
mortality due | 10 |
detection kit | 10 |
received tcz | 10 |
confirmed cap | 10 |
disease patients | 10 |
analysis showed | 10 |
global public | 10 |
atypical pneumonia | 10 |
disinfection pool | 10 |
patients may | 10 |
study group | 10 |
low incidence | 10 |
virus type | 10 |
hospitalised patients | 10 |
activation disease | 10 |
countries worldwide | 10 |
disease transmission | 10 |
dengue fever | 10 |
diagnostic accuracy | 10 |
long distance | 10 |
class ii | 10 |
healthcare systems | 10 |
outcomes among | 10 |
highly pathogenic | 10 |
potential risk | 10 |
within hours | 10 |
allowed us | 10 |
retrospective case | 10 |
average number | 10 |
major outbreak | 10 |
health risks | 10 |
written informed | 10 |
electronic medical | 10 |
nucleic acids | 10 |
familial cluster | 10 |
urgent need | 10 |
environmental factors | 10 |
measures among | 10 |
world bank | 10 |
haemophilus influenzae | 10 |
emergency department | 10 |
dendritic cells | 10 |
pneumonia caused | 10 |
times higher | 10 |
important lessons | 10 |
chinese government | 10 |
older adults | 10 |
start date | 10 |
compared using | 10 |
inactivated virus | 10 |
antigen level | 10 |
first time | 10 |
among healthcare | 10 |
ev vaccine | 10 |
case numbers | 10 |
spatial spread | 10 |
dengue virus | 10 |
many african | 10 |
critical cases | 10 |
observational studies | 10 |
female idus | 10 |
human infection | 10 |
early childhood | 10 |
neutrophil count | 9 |
household transmission | 9 |
conducted among | 9 |
newly infected | 9 |
apn gene | 9 |
pneumonia cases | 9 |
cytokine storms | 9 |
pearson correlation | 9 |
cases per | 9 |
qualitative study | 9 |
may result | 9 |
correlation analysis | 9 |
since january | 9 |
bacterial pathogens | 9 |
may play | 9 |
th march | 9 |
necrosis factor | 9 |
supportive care | 9 |
cumulative number | 9 |
prevention measures | 9 |
virus transmission | 9 |
antiviral agents | 9 |
studies reported | 9 |
laboratory abnormalities | 9 |
epidemic processes | 9 |
vaccine uptake | 9 |
positive rt | 9 |
medical research | 9 |
facemask use | 9 |
containment measures | 9 |
day seven | 9 |
study clinical | 9 |
serum antibody | 9 |
chemosensory disorders | 9 |
analysis using | 9 |
differential diagnosis | 9 |
novaferon group | 9 |
table shows | 9 |
viral transport | 9 |
protease inhibitor | 9 |
interim guidance | 9 |
previously reported | 9 |
cp infusion | 9 |
analyzed using | 9 |
bone marrow | 9 |
laboratory confirmation | 9 |
illness onset | 9 |
storm syndromes | 9 |
causative pathogens | 9 |
psi scores | 9 |
antigen levels | 9 |
distance truck | 9 |
higher among | 9 |
mean score | 9 |
pcr testing | 9 |
laboratory testing | 9 |
better understanding | 9 |
tongji hospital | 9 |
air quality | 9 |
dna vaccine | 9 |
primary case | 9 |
receiver operating | 9 |
northern italy | 9 |
harm reduction | 9 |
glass opacity | 9 |
transmission rate | 9 |
type measures | 9 |
reduction program | 9 |
preprocessing disinfection | 9 |
partial pressure | 9 |
human serum | 9 |
lactate dehydrogenase | 9 |
sc group | 9 |
laboratory values | 9 |
severe sepsis | 9 |
east asia | 9 |
recent years | 9 |
medical care | 9 |
swab specimens | 9 |
outbreak investigations | 9 |
province excluding | 9 |
since december | 9 |
mandatory mask | 9 |
cases generated | 9 |
regression model | 9 |
reporting delays | 9 |
gyeongbuk province | 9 |
renal disease | 9 |
olympic games | 9 |
acute infection | 9 |
findings suggest | 9 |
fever virus | 9 |
community health | 9 |
chronic obstructive | 9 |
unclear whether | 9 |
based screening | 9 |
allocate points | 9 |
may occur | 9 |
rural areas | 9 |
protective measure | 9 |
direct contact | 9 |
regression models | 9 |
fatal outcome | 9 |
using kit | 9 |
many cities | 9 |
cerebrospinal fluid | 9 |
nipah virus | 9 |
respiratory pathogen | 9 |
richards model | 9 |
antibody response | 9 |
cost savings | 9 |
abstract background | 9 |
days later | 9 |
macrophage activation | 9 |
affected areas | 9 |
literacy level | 9 |
one patient | 9 |
elevated levels | 9 |
herd immunity | 9 |
acquired weakness | 9 |
pulmonary disease | 9 |
superspreading events | 9 |
patients co | 9 |
general office | 9 |
specific antibodies | 9 |
abstract objectives | 9 |
will need | 9 |
much lower | 9 |
pcr results | 9 |
higher mortality | 9 |
bronchoalveolar lavage | 9 |
research ethics | 9 |
case definitions | 9 |
igm igg | 9 |
previous reports | 9 |
educational level | 9 |
moderate grade | 9 |
cp transfusion | 9 |
vaccine candidates | 9 |
high proportion | 9 |
broad spectrum | 8 |
west african | 8 |
suspected influenza | 8 |
swab samples | 8 |
controlled study | 8 |
clinical improvement | 8 |
serum samples | 8 |
repurposed drugs | 8 |
health response | 8 |
gold standard | 8 |
bacterial pneumonia | 8 |
pneumonia outbreak | 8 |
prediction models | 8 |
antiviral effects | 8 |
receptor antagonist | 8 |
previous study | 8 |
chikungunya virus | 8 |
medical history | 8 |
daily new | 8 |
study date | 8 |
medical residents | 8 |
based approach | 8 |
fever clinic | 8 |
time period | 8 |
coagulation parameters | 8 |
also showed | 8 |
chlamydia pneumoniae | 8 |
cov patients | 8 |
sustainable development | 8 |
chronic renal | 8 |
mild cases | 8 |
surgical masks | 8 |
identify patients | 8 |
infected persons | 8 |
effective antiviral | 8 |
therapeutic interventions | 8 |
recently published | 8 |
two doses | 8 |
human aminopeptidase | 8 |
mg kg | 8 |
saharan african | 8 |
artery lesions | 8 |
high quality | 8 |
room air | 8 |
animal health | 8 |
care settings | 8 |
clinical findings | 8 |
currently available | 8 |
among young | 8 |
square test | 8 |
lower risk | 8 |
large proportion | 8 |
baseline laboratory | 8 |
supply chain | 8 |
positive samples | 8 |
absolute value | 8 |
china date | 8 |
days post | 8 |
cumulative incidence | 8 |
virus isolation | 8 |
results suggest | 8 |
apn exon | 8 |
disease research | 8 |
clinical predictors | 8 |
suspected covid | 8 |
cumulative case | 8 |
reducing mortality | 8 |
storm syndrome | 8 |
cov surveillance | 8 |
facemask among | 8 |
study suggests | 8 |
respiration rates | 8 |
invasive mechanical | 8 |
mathematical modelling | 8 |
people living | 8 |
may provide | 8 |
international community | 8 |
term outcomes | 8 |
returning travellers | 8 |
general symptoms | 8 |
natural history | 8 |
flu group | 8 |
equine encephalitis | 8 |
sick patient | 8 |
provincial capital | 8 |
acute kidney | 8 |
saliva samples | 8 |
clinical severity | 8 |
international journal | 8 |
made available | 8 |
controlled trials | 8 |
severely ill | 8 |
one dose | 8 |
human parainfluenza | 8 |
study found | 8 |
increased significantly | 8 |
cases vs | 8 |
hospital infection | 8 |
zoonotic diseases | 8 |
assessed using | 8 |
new infections | 8 |
spatial dependency | 8 |
turning point | 8 |
carrier state | 8 |
coronavirus sars | 8 |
clinical outcome | 8 |
detected among | 8 |
study used | 8 |
infectious agents | 8 |
similar results | 8 |
care systems | 8 |
clinical samples | 8 |
also used | 8 |
symptomatic cases | 8 |
early identification | 8 |
health conditions | 8 |
four types | 8 |
risk groups | 8 |
first covid | 8 |
causative agent | 8 |
first study | 8 |
tested negative | 8 |
sample pooling | 8 |
developed countries | 8 |
previously described | 8 |
air pollutants | 8 |
like symptoms | 8 |
human movements | 8 |
cd cd | 8 |
cmos camera | 8 |
single dose | 8 |
formal healthcare | 8 |
nasal swab | 8 |
white cell | 8 |
fold increase | 8 |
disease clinical | 8 |
infectious agent | 8 |
febrile children | 8 |
laboratory criteria | 8 |
mers outbreak | 8 |
five years | 8 |
iv every | 8 |
several countries | 8 |
respiratory illnesses | 8 |
screening criteria | 8 |
included patients | 8 |
st century | 8 |
regression analysis | 8 |
concomitant pneumonia | 8 |
lrt samples | 8 |
pathological findings | 8 |
cov cases | 8 |
prolonged viral | 8 |
pao fio | 8 |
health issues | 8 |
days following | 8 |
therapeutic plasma | 8 |
daily number | 8 |
south america | 8 |
hiv infected | 8 |
routine clinical | 8 |
molecular diagnosis | 8 |
first cases | 8 |
avoiding touching | 8 |
lessons learned | 8 |
study protocol | 8 |
rate among | 8 |
nonpharmaceutical interventions | 8 |
based surveillance | 8 |
etiological agents | 8 |
per minute | 8 |
mortality associated | 8 |
transcription pcr | 8 |
health prevention | 8 |
precautions knowledge | 8 |
multiple vital | 8 |
laboratory parameters | 8 |
enterovirus infection | 8 |
physical examination | 8 |
lower levels | 8 |
suspect cases | 8 |
swine flu | 8 |
human interferon | 8 |
common symptoms | 8 |
risk group | 8 |
rapidly spread | 8 |
next pandemic | 8 |
suspected mers | 8 |
cell transplant | 8 |
less common | 8 |
obstructive pulmonary | 8 |
infectious pathogens | 7 |
internal medicine | 7 |
gatherings medicine | 7 |
australian pilgrims | 7 |
low levels | 7 |
study also | 7 |
bat origin | 7 |
lung inflammation | 7 |
host cell | 7 |
excluding hubei | 7 |
health facilities | 7 |
two studies | 7 |
ordinary citizens | 7 |
risk management | 7 |
normally distributed | 7 |
laboratory facilities | 7 |
nasogastric tube | 7 |
rsv infection | 7 |
recovered patients | 7 |
less severe | 7 |
high prevalence | 7 |
deceased patients | 7 |
cumulative cases | 7 |
publication bias | 7 |
control groups | 7 |
body fluids | 7 |
transmission phase | 7 |
will help | 7 |
two waves | 7 |
disease caused | 7 |
china clinical | 7 |
deaths occurred | 7 |
serological testing | 7 |
cell receptor | 7 |
expanded screening | 7 |
two thirds | 7 |
gel electrophoresis | 7 |
decision making | 7 |
sen university | 7 |
blood specimens | 7 |
confirmed patients | 7 |
three sections | 7 |
human subjects | 7 |
genomic characterization | 7 |
overall mortality | 7 |
serum levels | 7 |
virological assessment | 7 |
emerging infections | 7 |
two epidemic | 7 |
determine whether | 7 |
cell counts | 7 |
precautions training | 7 |
health professionals | 7 |
west nile | 7 |
two months | 7 |
health interventions | 7 |
antiviral effect | 7 |
accession number | 7 |
pneumococcal vaccination | 7 |
nile virus | 7 |
hemorrhagic fever | 7 |
health service | 7 |
health surveillance | 7 |
operating characteristic | 7 |
phase i | 7 |
protection equipment | 7 |
early epidemic | 7 |
lung involvement | 7 |
mass spectrometry | 7 |
april th | 7 |
randomized trial | 7 |
clean area | 7 |
high sensitivity | 7 |
dependent variable | 7 |
negative patients | 7 |
influenzae type | 7 |
via nasogastric | 7 |
new covid | 7 |
sewage samples | 7 |
febrile patients | 7 |
surveillance data | 7 |
increased mortality | 7 |
positive sars | 7 |
travel agents | 7 |
children hospitalized | 7 |
care facilities | 7 |
based methods | 7 |
maximum score | 7 |
early march | 7 |
increasing age | 7 |
consolidation ggo | 7 |
infection patients | 7 |
significant effect | 7 |
human cases | 7 |
using rt | 7 |
healthy individuals | 7 |
antiviral activity | 7 |
consider cytokine | 7 |
community members | 7 |
th april | 7 |
feb th | 7 |
renal function | 7 |
among females | 7 |
common cause | 7 |
enhanced surveillance | 7 |
study personnel | 7 |
transmission risk | 7 |
pneumonia associated | 7 |
receptor binding | 7 |
rural haiti | 7 |
emergency room | 7 |
protein levels | 7 |
calendar time | 7 |
iv tocilizumab | 7 |
communicable disease | 7 |
pneumococcal vaccine | 7 |
low risk | 7 |
equatorial guinea | 7 |
respiratory diseases | 7 |
rapid diagnostic | 7 |
doctor respondents | 7 |
cs laboratory | 7 |
sun yat | 7 |
sporadic cases | 7 |
class i | 7 |
treat covid | 7 |
systemic mast | 7 |
antibiotic resistance | 7 |
china excluding | 7 |
spread across | 7 |
response rate | 7 |
igg positive | 7 |
two peaks | 7 |
rna viruses | 7 |
seasonal trends | 7 |
affected countries | 7 |
cap patients | 7 |
demographic information | 7 |
serious adverse | 7 |
different populations | 7 |
health preparedness | 7 |
may explain | 7 |
hospital admissions | 7 |
disease associated | 7 |
optimal cut | 7 |
time polymerase | 7 |
air samples | 7 |
asymptomatic proportion | 7 |
controls vs | 7 |
zhejiang province | 7 |
expert group | 7 |
sensitivity analyses | 7 |
esam i | 7 |
sc tocilizumab | 7 |
clinical studies | 7 |
respiratory samples | 7 |
human rhinovirus | 7 |
age years | 7 |
side effects | 7 |
pneumonia clinical | 7 |
six months | 7 |
asymptomatic case | 7 |
antibiotic use | 7 |
clinical response | 7 |
among asymptomatic | 7 |
cases may | 7 |
sample collection | 7 |
three cases | 7 |
well known | 7 |
investigation strategies | 7 |
intubated patients | 7 |
medical resources | 7 |
virus detected | 7 |
salmonella typhi | 7 |
human movement | 7 |
igm antibody | 7 |
temporal profiles | 7 |
exclusion criteria | 7 |
wholesale market | 7 |
neutralizing antibody | 7 |
elsevier ltd | 7 |
infection risk | 7 |
plasma therapy | 7 |
referral hospital | 7 |
current status | 7 |
nk cells | 7 |
antibody levels | 7 |
public transport | 7 |
oropharyngeal saliva | 7 |
invasive ventilation | 7 |
surface contamination | 7 |
different age | 7 |
tertiary hospital | 7 |
authors contributed | 7 |
blood products | 7 |
disease progression | 7 |
received cp | 7 |
analysis revealed | 7 |
mild covid | 7 |
first step | 7 |
two methods | 7 |
large cohort | 7 |
effect model | 7 |
affiliated hospital | 7 |
imv requirement | 7 |
causative agents | 7 |
online version | 7 |
urgently needed | 7 |
data associated | 7 |
coronavirus indicating | 7 |
dimer levels | 7 |
health emergencies | 7 |
viral etiology | 7 |
severe coronavirus | 7 |
without mechanical | 7 |
various types | 7 |
early covid | 7 |
potential third | 7 |
severe community | 7 |
heat shock | 7 |
effective vaccine | 7 |
rural residents | 7 |
spss statistics | 7 |
two viruses | 7 |
severe course | 7 |
detected using | 7 |
results indicate | 7 |
dna vaccines | 7 |
induced fever | 7 |
lung tissue | 7 |
community acquired | 7 |
data suggest | 7 |
average age | 7 |
children years | 7 |
lung ct | 7 |
antiviral drug | 7 |
received iv | 7 |
determinant powers | 7 |
severe influenza | 7 |
flu season | 7 |
cov genomic | 7 |
reported case | 7 |
study included | 7 |
outbreak originating | 7 |
may help | 7 |
like particles | 7 |
susceptible individuals | 7 |
increasing number | 7 |
household contacts | 7 |
systematic reviews | 7 |
loading dose | 7 |
within two | 7 |
capsid protein | 7 |
every year | 7 |
transport medium | 7 |
clinical signs | 7 |
transmission chains | 7 |
five meteorological | 7 |
posterior oropharyngeal | 7 |
experienced two | 7 |
migration intensity | 7 |
blood lymphocytes | 7 |
using spss | 7 |
blood cells | 7 |
small sample | 7 |
younger age | 6 |
weather variables | 6 |
middle eastern | 6 |
reporting rate | 6 |
oral vaccine | 6 |
literature review | 6 |
routine laboratory | 6 |
health promotion | 6 |
vaccine strain | 6 |
status quo | 6 |
three patients | 6 |
escmid study | 6 |
countries may | 6 |
impact assessment | 6 |
independent variables | 6 |
three types | 6 |
crp level | 6 |
asymptomatic infection | 6 |
peak around | 6 |
behavior changes | 6 |
hospital mortality | 6 |
might lead | 6 |
among ordinary | 6 |
sentinel sites | 6 |
umrah mass | 6 |
sectional studies | 6 |
daily counts | 6 |
negative rt | 6 |
relative transmissibility | 6 |
reverse primer | 6 |
i statistic | 6 |
individuals aged | 6 |
multiplex pcr | 6 |
influenza pneumonia | 6 |
children may | 6 |
ct imaging | 6 |
disease course | 6 |
particulate matter | 6 |
viruses among | 6 |
greater decrease | 6 |
korea outbreak | 6 |
live attenuated | 6 |
mhc class | 6 |
igg antibody | 6 |
evidence base | 6 |
end date | 6 |
five countries | 6 |
one month | 6 |
systemic lupus | 6 |
reverse genetics | 6 |
confidence intervals | 6 |
ethnic groups | 6 |
pilot study | 6 |
chinese medicine | 6 |
apn cd | 6 |
different respiratory | 6 |
potential domestic | 6 |
generation time | 6 |
reported olfactory | 6 |
personal protection | 6 |
respiratory symptom | 6 |
took place | 6 |
widely used | 6 |
municipal health | 6 |
significant association | 6 |
turning points | 6 |
seafood wholesale | 6 |
inflammatory factor | 6 |
pediatric patients | 6 |
high fatality | 6 |
excess mortality | 6 |
low cost | 6 |
studies conducted | 6 |
pathogen detected | 6 |
broad range | 6 |
southern california | 6 |
qpcr solutions | 6 |
coronavirus cases | 6 |
million cases | 6 |
transport media | 6 |
rates among | 6 |
study groups | 6 |
large outbreak | 6 |
household members | 6 |
may cause | 6 |
will also | 6 |
may increase | 6 |
rapid antigen | 6 |
three major | 6 |
survival rates | 6 |
recently reported | 6 |
cause severe | 6 |
among males | 6 |
male patients | 6 |
children admitted | 6 |
written consent | 6 |
specimen collection | 6 |
neutrophil counts | 6 |
healthcare setting | 6 |
blood cultures | 6 |
acute lower | 6 |
segmented neutrophil | 6 |
older children | 6 |
epidemic outbreak | 6 |
highest rate | 6 |
important factor | 6 |
general practitioners | 6 |
health threats | 6 |
ongoing outbreak | 6 |
large sample | 6 |
influenza surveillance | 6 |
gustatory dysfunctions | 6 |
acute lung | 6 |
virus vaccines | 6 |
two different | 6 |
mobile device | 6 |
fell significantly | 6 |
democratic republic | 6 |
may require | 6 |
critical role | 6 |
ncov outbreak | 6 |
joint mission | 6 |
lower sensitivity | 6 |
stomatitis virus | 6 |
whole blood | 6 |
rapid detection | 6 |
kidney injury | 6 |
quarantine mandatory | 6 |
acid detection | 6 |
drug fever | 6 |
tested using | 6 |
flu test | 6 |
emerging novel | 6 |
wearing masks | 6 |
affiliated hospitals | 6 |
active surveillance | 6 |
taiwan cdc | 6 |
financial support | 6 |
pooling strategy | 6 |
nosocomial infection | 6 |
commercially available | 6 |
fibrin thrombi | 6 |
closely related | 6 |
standard care | 6 |
one third | 6 |
copies ml | 6 |
barr virus | 6 |
latin america | 6 |
generation interval | 6 |
sentinel surveillance | 6 |
emergency committee | 6 |
invasive disease | 6 |
tni levels | 6 |
general practice | 6 |
epidemic among | 6 |
oseltamivir mg | 6 |
host response | 6 |
suspected case | 6 |
medical workers | 6 |
educational levels | 6 |
time since | 6 |
people worldwide | 6 |
mitigation measures | 6 |
china showed | 6 |
positively associated | 6 |
mitigation strategies | 6 |
cov sub | 6 |
virus clearance | 6 |
coronary aneurysms | 6 |
antiviral agent | 6 |
new vaccine | 6 |
sectional survey | 6 |
least three | 6 |
radiological findings | 6 |
south east | 6 |
wide range | 6 |
among healthy | 6 |
clinical microbiology | 6 |
influenza among | 6 |
current pandemic | 6 |
primer probe | 6 |
zoonotic pathogens | 6 |
molecular epidemiology | 6 |
among others | 6 |
also suggested | 6 |
cell surface | 6 |
treating covid | 6 |
big data | 6 |
health advice | 6 |
significantly decreased | 6 |
demographic data | 6 |
using google | 6 |
study site | 6 |
likert scale | 6 |
highest among | 6 |
ferritin levels | 6 |
precautions among | 6 |
including deaths | 6 |
impacting compliance | 6 |
following tocilizumab | 6 |
wha member | 6 |
virus origins | 6 |
outbreak among | 6 |
lavage fluid | 6 |
asymptomatic transmission | 6 |
ill health | 6 |
cohort studies | 6 |
aspartate aminotransferase | 6 |
see supplementary | 6 |
showed significant | 6 |
reported hiv | 6 |
one respiratory | 6 |
supplementary data | 6 |
late february | 6 |
gustatory dysfunction | 6 |
therapeutic options | 6 |
abnormal coagulation | 6 |
since february | 6 |
lupus erythematosus | 6 |
high incidence | 6 |
vaccine protects | 6 |
chronic diseases | 6 |
get infected | 6 |
meningococcal vaccine | 6 |
cd count | 6 |
member nations | 6 |
imaging features | 6 |
significantly correlated | 6 |
one virus | 6 |
determined using | 6 |
supplementary materials | 6 |
test positive | 6 |
negative result | 6 |
nosocomial infections | 6 |
platelet count | 6 |
study among | 6 |
available data | 6 |
epidemic data | 6 |
nasopharyngeal specimens | 6 |
common cold | 6 |
cd cell | 6 |
last week | 6 |
interim guidelines | 6 |
entire population | 6 |
model based | 6 |
travel bans | 6 |
lower limbs | 6 |
subgroup analysis | 6 |
outbreak control | 6 |
basic reproductive | 6 |
newly diagnosed | 6 |
ev vaccines | 6 |
disease prevention | 6 |
ct manifestations | 6 |
incidence curve | 6 |
sc groups | 6 |
first report | 6 |
preventable diseases | 6 |
infectious causes | 6 |
directed therapies | 6 |
flow oxygen | 6 |
mc activation | 6 |
last case | 6 |
cov infections | 6 |
image processing | 6 |
hajj travel | 6 |
global surveillance | 6 |
infections due | 6 |
common pathogen | 6 |
travel health | 6 |
extracted using | 6 |
pilgrims attending | 6 |
genomic hubs | 6 |
requiring mechanical | 6 |
cell therapy | 6 |
rapid flu | 6 |
three groups | 6 |
psi scale | 6 |
sewage disinfection | 6 |
sodium hypochlorite | 6 |
children less | 6 |
center study | 6 |
treatment options | 6 |
international airport | 6 |
randomised trial | 6 |
without tcz | 6 |
activity compliance | 6 |
may depend | 6 |
death rate | 6 |
klebsiella pneumoniae | 6 |
moderate covid | 6 |
chest radiograph | 6 |
pathogenic coronavirus | 6 |
adverse effects | 6 |
wuhan trajectories | 6 |
health hazards | 6 |
higher viral | 6 |
higher compared | 6 |
genetic determinants | 6 |
diagnostic performance | 6 |
home orders | 6 |
low sensitivity | 6 |
undifferentiated fever | 6 |
illness among | 6 |
studies used | 6 |
organ transplant | 6 |
related deaths | 6 |
will allow | 6 |
higher positive | 6 |
clinical care | 6 |
using irt | 6 |
hajj rituals | 6 |
vulnerable populations | 6 |
containing covid | 6 |
bootstrap value | 6 |
islamic year | 6 |
cases might | 6 |
response plan | 6 |
positive blood | 6 |
mild disease | 6 |
multiple countries | 6 |
may reflect | 6 |
severe symptoms | 6 |
sars cases | 6 |
severe bronchiolitis | 6 |
severity index | 6 |
china joint | 6 |
marneffei infection | 6 |
slightly higher | 6 |
proinflammatory cytokines | 6 |
cases reached | 6 |
lancet infectious | 6 |
different npis | 6 |
female case | 6 |
healthcare services | 6 |
gene expression | 6 |
first days | 6 |
symptomatic patients | 6 |
skilled nursing | 6 |
rights reserved | 6 |
local health | 6 |
ongoing covid | 6 |
remain unclear | 6 |
remains unknown | 6 |
concomitant corticosteroids | 6 |
epidemiological investigation | 6 |
prevention strategies | 6 |
reduced mortality | 6 |
low viral | 6 |
general isolation | 6 |
health information | 6 |
three times | 6 |
health insurance | 6 |
factors impacting | 6 |
past weeks | 6 |
poor countries | 6 |
economic losses | 6 |
innate immune | 6 |
year old | 6 |
sharps disposal | 6 |
patients positive | 6 |
health challenges | 6 |
immune cells | 6 |
detect sars | 6 |
six different | 6 |
common pathogens | 6 |
mean incidence | 6 |
first month | 6 |
chest distress | 6 |
virus vaccine | 6 |
samples collected | 6 |
epidemic curves | 6 |
vesicular stomatitis | 6 |
shock syndrome | 6 |
threshold value | 6 |
prevention kits | 6 |
msc therapy | 6 |
device traces | 6 |
adults hospitalized | 6 |
attenuated vaccine | 6 |
infection using | 6 |
classification model | 6 |
first affiliated | 6 |
bacterial agents | 6 |
associated infections | 6 |
indicating person | 6 |
reported confirmed | 6 |
drug users | 6 |
associated pneumonia | 6 |
median scores | 6 |
small proportion | 6 |
two models | 6 |
type diabetes | 6 |
nasal carriage | 6 |
emerging infection | 6 |
series study | 6 |
direct pcr | 6 |
hla class | 6 |
summer months | 6 |
four patients | 6 |
emerging pathogens | 6 |
zhejiang university | 6 |
sequence data | 6 |
respiratory droplets | 6 |
becoming infected | 6 |
neisseria meningitidis | 6 |
subunit vaccine | 6 |
nasal self | 6 |
seven respiratory | 6 |
mg via | 6 |
mers patients | 5 |
acute onset | 5 |
serum creatinine | 5 |
vaccine preventable | 5 |
regression analyses | 5 |
environmental health | 5 |
including influenza | 5 |
medical treatment | 5 |
died patients | 5 |
medical sciences | 5 |
secondary epidemic | 5 |
sharp instruments | 5 |
laboratory capacity | 5 |
patient groups | 5 |
another important | 5 |
across africa | 5 |
phase iii | 5 |
school closures | 5 |
doubling times | 5 |
electronic surveillance | 5 |
pandemic period | 5 |
health status | 5 |
chiang rai | 5 |
measures implemented | 5 |
core group | 5 |
epidemic progression | 5 |
related infections | 5 |
higher educational | 5 |
van doremalen | 5 |
dromedary camel | 5 |
hospital outbreak | 5 |
well documented | 5 |
probable sars | 5 |
blood purification | 5 |
breaths per | 5 |
infection spread | 5 |
health problems | 5 |
future work | 5 |
significant proportion | 5 |
infected person | 5 |
significantly better | 5 |
full text | 5 |
gender groups | 5 |
day duration | 5 |
female cases | 5 |
infection clinical | 5 |
well studied | 5 |
cov rna | 5 |
disease among | 5 |
monthly reported | 5 |
malaria endemic | 5 |
detailed information | 5 |
following two | 5 |
innate immunity | 5 |
viral agents | 5 |
providing food | 5 |
asymptomatic subjects | 5 |
inflammatory responses | 5 |
individual interviews | 5 |
functional receptor | 5 |
new zoonotic | 5 |
adverse outcomes | 5 |
evidence based | 5 |
tropical medicine | 5 |
telephone interview | 5 |
guangdong province | 5 |
laboratory investigation | 5 |
comparative study | 5 |
escherichia coli | 5 |
associated mrsa | 5 |
subjects aged | 5 |
capital cities | 5 |
three vital | 5 |
epidemiological parameters | 5 |
remains unclear | 5 |
idu hiv | 5 |
inflammatory cytokine | 5 |
funnel plot | 5 |
cellular immune | 5 |
absolute lymphocyte | 5 |
future prospects | 5 |
care test | 5 |
enzyme immunoassay | 5 |
type i | 5 |
significant correlations | 5 |
mixed infections | 5 |
retrospective analysis | 5 |
past outbreaks | 5 |
emergency preparedness | 5 |
search queries | 5 |
continuous data | 5 |
prevent influenza | 5 |
ev infection | 5 |
endotracheal intubation | 5 |
recrudescent case | 5 |
family medicine | 5 |
factors related | 5 |
typhoid fever | 5 |
central vietnam | 5 |
densely populated | 5 |
pcr detection | 5 |
may develop | 5 |
clinical use | 5 |
highly contagious | 5 |
countries including | 5 |
scoring system | 5 |
improved outcomes | 5 |
died days | 5 |
ischemic heart | 5 |
npi types | 5 |
patient rooms | 5 |
washing hands | 5 |
international cooperation | 5 |
novel pathogens | 5 |
independent predictive | 5 |
hospital environmental | 5 |
scoring systems | 5 |
monoclonal antibodies | 5 |
highly effective | 5 |
net cost | 5 |
symptoms may | 5 |
sample sizes | 5 |
genome sequences | 5 |
local case | 5 |
school year | 5 |
fever clinics | 5 |
bat sars | 5 |
hyaline membrane | 5 |
seroprevalence among | 5 |
mass index | 5 |
study indicated | 5 |
congo haemorrhagic | 5 |
neurological disorders | 5 |
lung pathology | 5 |
past decade | 5 |
like particle | 5 |
viral dose | 5 |
distributed variables | 5 |
lombardy region | 5 |
sexually transmitted | 5 |
pcr positive | 5 |
methods used | 5 |
mental health | 5 |
reported covid | 5 |
controlled studies | 5 |
positively correlated | 5 |
population size | 5 |
hemodialysis patients | 5 |
still remains | 5 |
surveillance program | 5 |
care practice | 5 |
outbreak associated | 5 |
behavior change | 5 |
participants reported | 5 |
major cause | 5 |
kd incidence | 5 |
patients recovered | 5 |
many patients | 5 |
coagulation function | 5 |
clinical disease | 5 |
host cells | 5 |
long time | 5 |
control practices | 5 |
mildly symptomatic | 5 |
ethics board | 5 |
haitian children | 5 |
care institutions | 5 |
occupational exposure | 5 |
national surveillance | 5 |
among hcws | 5 |
south korean | 5 |
foster city | 5 |
infection rates | 5 |
sports events | 5 |
childhood ari | 5 |
conjugate vaccine | 5 |
study shows | 5 |
distancing interventions | 5 |
virus strains | 5 |
median duration | 5 |
among male | 5 |
index case | 5 |
negative binomial | 5 |
multiorgan failure | 5 |
large scale | 5 |
healthy volunteers | 5 |
novel sars | 5 |
taqman array | 5 |
animal models | 5 |
eight patients | 5 |
new england | 5 |
driven analysis | 5 |
respiratory function | 5 |
favipiravir treatment | 5 |
patients within | 5 |
daily covid | 5 |
center experience | 5 |
january th | 5 |
patients undergoing | 5 |
negative bacteria | 5 |
vp capsid | 5 |
human migrations | 5 |
promising vaccine | 5 |
three different | 5 |
scale outbreak | 5 |
will continue | 5 |
hospital staff | 5 |
absent pleural | 5 |
fusion protein | 5 |
disease pandemic | 5 |
yet another | 5 |
higher proportion | 5 |
clinical decision | 5 |
cases occurred | 5 |
opportunistic infections | 5 |
new year | 5 |
effective control | 5 |
recommended vaccines | 5 |
curative effect | 5 |
african union | 5 |
step rt | 5 |
chimeric antigen | 5 |
highest risk | 5 |
phylogenetic analysis | 5 |
vice versa | 5 |
study participants | 5 |
dimer level | 5 |
np swabs | 5 |
associated cytokine | 5 |
home quarantine | 5 |
clinical suspicion | 5 |
highly suspected | 5 |
host immune | 5 |
extracorporeal membrane | 5 |
kidney disease | 5 |
spatiotemporal association | 5 |
quantitative rt | 5 |
administrative cities | 5 |
pacific region | 5 |
pneumococcal conjugate | 5 |
hearing loss | 5 |
positive specimens | 5 |
among adults | 5 |
severely affected | 5 |
care tests | 5 |
recrudescence events | 5 |
human papillomavirus | 5 |
growth dynamics | 5 |
research agenda | 5 |
growth parameter | 5 |
beginning march | 5 |
independent risk | 5 |
endemic area | 5 |
potential impact | 5 |
viral nucleic | 5 |
border control | 5 |
three clusters | 5 |
multivariate logistic | 5 |
total viral | 5 |
march st | 5 |
daily case | 5 |
increasing numbers | 5 |
church cluster | 5 |
transcriptase pcr | 5 |
based service | 5 |
preventing influenza | 5 |
relatively low | 5 |
curve analysis | 5 |
late december | 5 |
tumor necrosis | 5 |
urban residents | 5 |
protein molecule | 5 |
development goals | 5 |
first draft | 5 |
severe groups | 5 |
type ii | 5 |
icu ward | 5 |
influenza season | 5 |
complete lockdowns | 5 |
troponin i | 5 |
first peak | 5 |
among hospital | 5 |
pneumonia severity | 5 |
may vary | 5 |
antigen receptor | 5 |
toxic shock | 5 |
time data | 5 |
tests performed | 5 |
open debate | 5 |
search volumes | 5 |
control covid | 5 |
hemophagocytic lymphohistiocytosis | 5 |
asymptomatic contact | 5 |
exposure experience | 5 |
task force | 5 |
active symptomatic | 5 |
treatment strategies | 5 |
isolation icu | 5 |
different rt | 5 |
countries will | 5 |
biological samples | 5 |
mg day | 5 |
presumed asymptomatic | 5 |
order neighbouring | 5 |
group i | 5 |
critical covid | 5 |
branching process | 5 |
later phase | 5 |
idu population | 5 |
outpatient clinics | 5 |
patients diagnosed | 5 |
japanese citizens | 5 |
cases including | 5 |
environmental hygiene | 5 |
response epidemiology | 5 |
simultaneous implementation | 5 |
supplemental oxygen | 5 |
every years | 5 |
excessive immune | 5 |
risk among | 5 |
likely due | 5 |
novaferon treatment | 5 |
position paper | 5 |
multiple npis | 5 |
nafamostat administration | 5 |
bilateral infiltrates | 5 |
convalescent human | 5 |
cd counts | 5 |
group received | 5 |
probable bat | 5 |
international arrivals | 5 |
children presenting | 5 |
encephalitis virus | 5 |
care patients | 5 |
patient contact | 5 |
consecutive patients | 5 |
nerve conduction | 5 |
higher levels | 5 |
ibm spss | 5 |
severe ards | 5 |
conduction studies | 5 |
changing epidemiology | 5 |
poisson regression | 5 |
situation reports | 5 |
virulent revertants | 5 |
deaths worldwide | 5 |
total lymphocyte | 5 |
north america | 5 |
regression discriminant | 5 |
research project | 5 |
among elderly | 5 |
ordinary japanese | 5 |
ace receptor | 5 |
care hospital | 5 |
qualified level | 5 |
study highlights | 5 |
initial phase | 5 |
specimens tested | 5 |
migrant population | 5 |
pandemic caused | 5 |
lung infiltrates | 5 |
structural proteins | 5 |
shiraz university | 5 |
health policy | 5 |
health outcomes | 5 |
occupational health | 5 |
bilateral pneumonia | 5 |
global supply | 5 |
global burden | 5 |
antibodies among | 5 |
reduce mortality | 5 |
many pilgrims | 5 |
scores alone | 5 |
hajj health | 5 |
genbank accession | 5 |
lethal challenge | 5 |
virus may | 5 |
developed using | 5 |
cause mortality | 5 |
clinical presentations | 5 |
related health | 5 |
significant impact | 5 |
chest computed | 5 |
creatine kinase | 5 |
pneumococcal infections | 5 |
gastrointestinal tract | 5 |
new infectious | 5 |
respiratory syndromeadvancing | 5 |
reducing risk | 5 |
imported case | 5 |
across countries | 5 |
rna genome | 5 |
clinical diagnosis | 5 |
neighbouring provinces | 5 |
secondary infections | 5 |
among different | 5 |
measures including | 5 |
resistant bacteria | 5 |
deaths among | 5 |
patient described | 5 |
medical record | 5 |
examined whether | 5 |
zoonotic disease | 5 |
successful treatment | 5 |
carrier transmission | 5 |
related coronavirus | 5 |
mild infections | 5 |
body mass | 5 |
molecular diagnostics | 5 |
clinical laboratory | 5 |
must plan | 5 |
cell entry | 5 |
collected using | 5 |
clinical status | 5 |
measures taken | 5 |
adult population | 5 |
wave epidemic | 5 |
died within | 5 |
cell epitopes | 5 |
epitope peptide | 5 |
eligibility criteria | 5 |
generation sequencing | 5 |
additional health | 5 |
exact time | 5 |
intervention group | 5 |
practices towards | 5 |
clinical examination | 5 |
old male | 5 |
higher incidence | 5 |
detect respiratory | 5 |
sensitivity analysis | 5 |
prognostic factors | 5 |
three weeks | 5 |
phylogenetic tree | 5 |
control interventions | 5 |
array card | 5 |
pneumonia emergency | 5 |
cellular therapies | 5 |
histoplasma antigen | 5 |
polio vaccine | 5 |
case identification | 5 |
longer time | 5 |
days prior | 5 |
last segment | 5 |
factors influencing | 5 |
publicly reported | 5 |
mycoplasma pneumoniae | 5 |
mg subcutaneously | 5 |
johns hopkins | 5 |
primary source | 5 |
seasonal flu | 5 |
daily reported | 5 |
virus replication | 5 |
alanine aminotransferase | 5 |
normal distribution | 5 |
human primates | 5 |
pcr tests | 5 |
emergency management | 5 |
smoking status | 5 |
prognostic scoring | 5 |
targeted therapy | 5 |
accurate diagnosis | 5 |
inspired oxygen | 5 |
infection group | 5 |
descriptive statistics | 5 |
received one | 5 |
rescue treatment | 5 |
death rates | 5 |
outbreak response | 5 |
future epidemics | 5 |
organisms detected | 5 |
pharyngeal swabs | 5 |
invasive pneumococcal | 5 |
risk perception | 5 |
case management | 5 |
multiple sclerosis | 5 |
systems must | 5 |
defined according | 5 |
lower viral | 5 |
nasopharyngeal aspirate | 5 |
prothrombin time | 5 |
three studies | 5 |
data support | 5 |
low prevalence | 5 |
evidence suggests | 5 |
underlying disease | 5 |
line list | 5 |
saudi authorities | 5 |
infected adults | 5 |
moh mers | 5 |
infection season | 5 |
well established | 5 |
pool sizes | 5 |
ncov patients | 5 |
identified three | 5 |
infection management | 5 |
patients met | 5 |
human health | 5 |
neighboring countries | 5 |
severe outcomes | 5 |
significant factor | 5 |
viral haemorrhagic | 5 |
highly infectious | 5 |
rna virus | 5 |
kd may | 5 |
neuraminidase inhibitors | 5 |
implemented early | 5 |
care doctors | 5 |
cov may | 5 |
may reduce | 5 |
unknown origin | 5 |
protective immunity | 5 |
also assessed | 5 |
potential use | 5 |
many clinical | 5 |
lupus anticoagulant | 5 |
five weeks | 5 |
short term | 5 |
different trajectories | 5 |
developed severe | 5 |
two days | 5 |
acute phase | 5 |
one sample | 5 |
effects model | 5 |
available parameters | 5 |
study aimed | 5 |
health consequences | 5 |
long incubation | 5 |
proprotein convertases | 5 |
thermal image | 5 |
future studies | 5 |
statistical power | 5 |
traditional chinese | 5 |
veterinary personnel | 5 |
interferon beta | 5 |
triage guidelines | 4 |
maximum likelihood | 4 |
susceptible population | 4 |
study enrolled | 4 |
female hiv | 4 |
primary data | 4 |
peak levels | 4 |
confirmed mers | 4 |
lateral flow | 4 |
software version | 4 |
nursing facility | 4 |
significantly improved | 4 |
neonatal mice | 4 |
histocompatibility complex | 4 |
iv twice | 4 |
social activities | 4 |
sars transmission | 4 |
enrolled patients | 4 |
mycobacterium tuberculosis | 4 |
genome sequencing | 4 |
disease epidemic | 4 |
healthcare delivery | 4 |
health officers | 4 |
main routes | 4 |
report questionnaires | 4 |
investigation team | 4 |
isolation precautions | 4 |
many studies | 4 |
us food | 4 |
may pose | 4 |
improved clinical | 4 |
us dollars | 4 |
implementation status | 4 |
cd cells | 4 |
will enable | 4 |
serious infections | 4 |
propensity scores | 4 |
four different | 4 |
tac assay | 4 |
tocilizumab treatment | 4 |
vero cell | 4 |
high rates | 4 |
evd outbreak | 4 |
significant risk | 4 |
infection date | 4 |
lower seroprevalence | 4 |
rv detection | 4 |
mortality significantly | 4 |
four medical | 4 |
secondary transmission | 4 |
illness surveillance | 4 |
preventive measure | 4 |
new framework | 4 |
wide variety | 4 |
old age | 4 |
lung function | 4 |
axillary temperature | 4 |
hospital workers | 4 |
membrane formation | 4 |
diagnostic capacity | 4 |
confirmed pneumonia | 4 |
year study | 4 |
testing kits | 4 |
treatment protocol | 4 |
major clusters | 4 |
epidemic source | 4 |
another limitation | 4 |
human mobility | 4 |
epidemic dynamics | 4 |
progressive respiratory | 4 |
infecting respiratory | 4 |
radiography showed | 4 |
great threat | 4 |
remains largely | 4 |
chikungunya outbreak | 4 |
china severe | 4 |
lbs requests | 4 |
capital city | 4 |
rapid test | 4 |